Zeitschriftenaufsatz | 2020 Open Access

A WAO - ARIA - GA2LEN consensus document on molecular-based allergy diagnosis (PAMD@): Update 2020

Autor:in
Ansotegui, I. J.; Melioli, Giovanni; canonica, giorgio walter; Gomez, Rene Maximiliano; Jensen-Jarolim, Erika; Ebisawa, Motohiro; Luengo, Olga; Caraballo, Luis; Passalacqua, Giovanni; Poulsen, Lars; Savi, Eleonora; Zuberbier, Torsten; Villa, E; Oppenheimer, John; Asero, Riccardo; Bernstein, Jonathan A.; Bousquet, Jean; Cardona, Victoria; Cox, Linda; Demoly, Pascal; Ferreira, Fatima; Giavina-Bianchi, Pedro; González-Díaz, Sandra; Jakob, Thilo; Tanno, Luciana; Kleine-Tebbe, J.; Levin, Michael; Martin, Bryan; Matricardi, Paolo; Monge-Ortega, Olga Patricia; Almeida, Mario Morais; Nunes, Carlos; Martell, Jose Antonio Ortega; Renz, Prof. Dr Harald Renz; Rosario, Nelson; Rouadi, Philip W.; Ruiba, Alessia; Sampson, Hugh; Sanchez Borges, M.; Scala, Enrico; Schmid, Peter; Senna, Gianenrico; Sisul, J. C.; Tang, Mimi; Valenta, Richard; van Hage, Marianne; Wong, Gary WK; Yanez, Anahi
Publikationen als Autor:in / Herausgeber:in der Vetmeduni
Jensen-Jarolim, Erika
Journal
World Allergy Organization Journal
Schlagwörter
Diagnosis; Molecular allergy; Cross reactivity; Panallergen; Specific IgE; PAMD@
Dokumenten­typ
Originalarbeit
CC Lizenz
CC-BY-NC-ND
Open Access Type
Gold
ISSN/eISSN
1939-4551 -
DOI
Öffnen URL 10.1016/j.waojou.2019.100091
WoS ID
Öffnen URL WOS:000523267300002
PubMed ID
Öffnen URL MEDLINE:32180890

Weitere Details

Band
13
Nummer
2
Seiten­anzahl
46
Precision allergy molecular diagnostic applications (PAMD@) is increasingly entering routine care. Currently, more than 130 allergenic molecules from more than 50 allergy sources are commercially available for in vitro specific immunoglobulin E (sIgE) testing. Since the last publication of this consensus document, a great deal of new information has become available regarding this topic, with over 100 publications in the last year alone. It thus seems quite reasonable to publish an update. It is imperative that clinicians and immunologists specifically trained in allergology keep abreast of the new and rapidly evolving evidence available for PAMD@. PAMD@ may initially appear complex to interpret; however, with increasing experience, the information gained provides relevant information for the allergist. This is especially true for food allergy, Hymenoptera allergy, and for the selection of allergen immunotherapy. Nevertheless, all sIgE tests, including PAMD@, should be evaluated within the framework of a patient's clinical history, because allergen sensitization does not necessarily imply clinical relevant allergies. Precision allergy molecular diagnostic applications (PAMD@) is increasingly entering routine care. Currently, more than 130 allergenic molecules from more than 50 allergy sources are commercially available for in vitro specific immunoglobulin E (sIgE) testing. Since the last publication of this consensus document, a great deal of new information has become available regarding this topic, with over 100 publications in the last year alone. It thus seems quite reasonable to publish an update. It is imperative that clinicians and immunologists specifically trained in allergology keep abreast of the new and rapidly evolving evidence available for PAMD@. PAMD@ may initially appear complex to interpret; however, with increasing experience, the information gained provides relevant information for the allergist. This is especially true for food allergy, Hymenoptera allergy, and for the selection of allergen immunotherapy. Nevertheless, all sIgE tests, including PAMD@, should be evaluated within the framework of a patient's clinical history, because allergen sensitization does not necessarily imply clinical relevant allergies.

Download
 RDF/XML-Format
 JSON-LD-Format
 Turtle-Format
 N3-Format